Format

Send to

Choose Destination
Mol Neurodegener. 2015 Dec 1;10:63. doi: 10.1186/s13024-015-0060-5.

Loss of parkin promotes lipid rafts-dependent endocytosis through accumulating caveolin-1: implications for Parkinson's disease.

Cha SH1,2, Choi YR1,2,3, Heo CH4, Kang SJ1,2,3, Joe EH1,2,3, Jou I1,2,3, Kim HM4, Park SM5,6,7.

Author information

1
Department of Pharmacology, Ajou University School of Medicine, 164, Worldcup-ro, Yeongtong-gu, Suwon, 16499, Korea.
2
Chronic Inflammatory Disease Research Center, Ajou University School of Medicine, Suwon, Korea.
3
Neuroscience Graduate Program, Ajou University School of Medicine, Suwon, Korea.
4
Department of Chemistry, Ajou University, Suwon, Korea.
5
Department of Pharmacology, Ajou University School of Medicine, 164, Worldcup-ro, Yeongtong-gu, Suwon, 16499, Korea. sangmyun@ajou.ac.kr.
6
Chronic Inflammatory Disease Research Center, Ajou University School of Medicine, Suwon, Korea. sangmyun@ajou.ac.kr.
7
Neuroscience Graduate Program, Ajou University School of Medicine, Suwon, Korea. sangmyun@ajou.ac.kr.

Abstract

BACKGROUND:

Parkinson's disease (PD) is characterized by progressive loss of midbrain dopaminergic neurons, resulting in motor dysfunctions. While most PD is sporadic in nature, a significant subset can be linked to either autosomal dominant or recessive mutations. PARK2, encoding the E3 ubiquitin ligase, parkin, is the most frequently mutated gene in autosomal recessive early onset PD. It has recently been reported that PD-associated gene products such as PINK1, α-synuclein, LRRK2, and DJ-1, as well as parkin associate with lipid rafts, suggesting that the dysfunction of these proteins in lipid rafts may be a causal factor of PD. Therefore here, we examined the relationship between lipid rafts-related proteins and parkin.

RESULTS:

We identified caveolin-1 (cav-1), which is one of the major constituents of lipid rafts at the plasma membrane, as a substrate of parkin. Loss of parkin function was found to disrupt the ubiquitination and degradation of cav-1, resulting in elevated cav-1 protein level in cells. Moreover, the total cholesterol level and membrane fluidity was altered by parkin deficiency, causing dysregulation of lipid rafts-dependent endocytosis. Further, cell-to-cell transmission of α-synuclein was facilitated by parkin deficiency.

CONCLUSIONS:

Our results demonstrate that alterations in lipid rafts by the loss of parkin via cav-1 may be a causal factor of PD, and cav-1 may be a novel therapeutic target for PD.

PMID:
26627850
PMCID:
PMC4666086
DOI:
10.1186/s13024-015-0060-5
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center